News & Views | Published:

Decade in review—dyslipidaemia

Resurgence of targets and compounds to treat dyslipidaemia

Nature Reviews Cardiology volume 11, pages 629631 (2014) | Download Citation

Over the past decade, we have witnessed the unparalleled success of statins to treat dyslipidaemia. Target identification by Mendelian randomization, human monoclonal antibodies, gene therapy, RNA-based targets, and atherogenic lipoproteins other than LDL cholesterol have fuelled intense development efforts that might bear fruit in the very near future.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350, 1495–1504 (2004).

  2. 2.

    et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352, 1425–1435 (2005).

  3. 3.

    et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195–2207 (2008).

  4. 4.

    et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 114, 1729–1735 (2006).

  5. 5.

    et al. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler. Thromb. Vasc. Biol. 28, 2303–2304 (2008).

  6. 6.

    , , & Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301, 2331–2339 (2009).

  7. 7.

    et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat. Genet. 45, 1345–1352 (2013).

  8. 8.

    et al. Effect of a monoclonal antibodies to PCSK9 on LDL cholesterol. N. Engl. J. Med. 366, 1108–1118 (2012).

  9. 9.

    , , & Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N. Engl. J. Med. 371, 32–41 (2014).

  10. 10.

    The TG and HDL Group of the Exome Sequencing Project, National, Heart, Lung, and Blood Institute. Loss-of-function mutations in APOC3, triglycerides, and coronary heart disease. N. Engl. J. Med. 371, 22–31 (2014).

Download references

Author information

Affiliations

  1. Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands.

    • John J. P. Kastelein

Authors

  1. Search for John J. P. Kastelein in:

Competing interests

J.J.P.K. declares that he has acted as a consultant and received honouraria from the following companies: Aegerion, Amgen, AstraZeneca, Atheronova, Boehringer Ingelheim, Catabasis, Cerenis, CSL Behring, Dezima Pharmaceuticals, Eli Lilly, Esperion, Genzyme, Isis, Merck, Novartis, Omthera, Pronova, Regeneron, Sanofi, The Medicines Company, UniQure, and Vascular Biogenics.

Corresponding author

Correspondence to John J. P. Kastelein.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrcardio.2014.132

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing